AtaiBeckley Inc.

Company identity and history

• Formed in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited.
• In December 2025, redomiciled from the Netherlands to the United States via Luxembourg; merged into atai Life Sciences Luxembourg S.A., which converted to a Delaware corporation named AtaiBeckley Inc.
• Publicly reports as AtaiBeckley Inc. and is the successor issuer to Atai Beckley N.V. under Rule 12g-3(a).

Business focus

• Clinical-stage biotechnology company focused on mental health disorders, developing psychedelic-based neuroplastogens and related compounds.
• Aims to deliver rapid-acting, convenient treatments that address core symptoms, quality of life, and lasting change.
• Maintains a diversified pipeline with both psychedelic-derived and non-psychedelic programs, plus a drug-discovery program focused on non-hallucinogenic 5-HT2A receptor (5-HT2AR) agonists.

Pipeline and core programs

• BPL-003: Nasal spray of mebufotenin (5-MeO-DMT) benzoate for treatment-resistant depression (TRD).
• VLS-01: Buccal film formulation of dimethyltryptamine (DMT) for TRD.
• EMP-01: Oral formulation of the R-enantiomer of MDMA (R-MDMA) for social anxiety disorder (SAD).
• Novel 5-HT2A/2C agonists: Drug discovery program to identify non-hallucinogenic 5-HT2A agonists for TRD and opioid use disorder (OUD).
• The portfolio includes psychedelic-like compounds, optimized variants, and non-psychedelic approaches.

Intellectual property

• As of December 31, 2025, the portfolio includes over 100 issued patents and over 200 pending patent applications worldwide.
• Key programs with dedicated IP coverage:
  • VLS-01: DMT transmucosal formulations and uses, with multiple U.S. patents and foreign filings.
  • BPL-003: Benzoate salt of 5-MeO-DMT and related forms, with issued and pending patents.
  • EMP-01: R-MDMA, with patents covering salts, forms, and uses.
  • Additional families covering non-hallucinogenic 5-HT2A agonists and related compounds.
• Patent expirations are generally projected between 2041 and 2046, excluding potential term adjustments or extensions.

Clinical and regulatory status

• Programs span preclinical work through Phase 2 and Phase 3 design considerations.
• Regulatory activity:
  • End-of-Phase 2 discussions with FDA for BPL-003; Phase 3 program design anticipated in 2026.
  • VLS-01 is in Phase 2 (Elumina) with topline data expected in H2 2026.
• Potential EU pathways include centralized and national marketing authorizations, data and market exclusivity, expedited development concepts, and post-approval obligations including pharmacovigilance.

Financial position and liquidity

• Net loss: $660.0 million in 2025; $149.3 million in 2024.
• Cash and equivalents: $85.3 million; short-term securities: $135.4 million (as of December 31, 2025).
• Based on current plans, cash and short-term securities are expected to fund operations into 2029.
• Revenue will depend on regulatory approvals and successful commercialization of product candidates.

Capital raising and funding highlights

• February 2025: Public offering of 26,190,477 shares; net proceeds about $51.9 million; underwriter option exercised for additional ~3.93 million shares (+$7.8 million).
• October 2025: Public offering of 23,725,000 shares; net proceeds about $121.7 million; underwriter option exercised for ~3.56 million shares (+$18.2 million).
• November 2022: Open Market Sale Agreement with Jefferies (ATM program) with availability up to $150.0 million.
• Ongoing use of shelf registration (Form S-3) with periodic prospectus supplements.

People and locations

• Employees: 99 full-time employees; 18 contractors/consultants (as of December 31, 2025).
• Nualtis subsidiary: 23 employees and 2 consultants.
• Geographic distribution: ~40% in the United Kingdom; ~30% in the United States; ~25% in Canada; remainder in other European locations.
• Headquarters: 250 West 34th Street, New York, NY 10119.
• Website: www.ataibeckley.com

Corporate strategy and partnerships

• Maintains a patient-impact initiative that embeds lived experience and partners with patient advocates (e.g., PsyPAN) to inform development, participant experience, and care models.
• Holds equity interests in other entities and engages in collaborations and in-licensing related to its programs and platforms, including strategic investments via platform companies.

Additional notes

• The company emphasizes a diversified mix of psychedelic-based neuroplastogens and non-hallucinogenic agents, with attention to rapid onset, durability, and integration with existing care pathways.
• The pipeline and IP footprint support development and potential commercialization across depression, TRD, SAD, anxiety, and related conditions, subject to regulatory approvals.